Click here for 2016 Registration

Technology Sponsors



Beuhler Motor

Media Partners

On Drug Delivery
Can Biotech
Current Partnering
Drug Development & Delivery
Massachusetts Life Sciences Center
MCD Group
Med Device Online
Medical News Today
Technology Networks

Executive Sponsors

Cambridge Consultants

Associate Sponsors


Technology Sponsors

Caisson Biotech
Credence MedSystems
Cristal Therapeutics
Delta Mod Tech
DisperSol Technologies LLC
Enable Injections
Glide Technologies
Insulet Corporation
Monosol RX
Oval Medical
PKA SoftTouch
Salvona Technologies
Sensile Medical
Serina Therapeutics
Terumo Medical


Baumann Group
Beuhler Motor
Precision Engineered Products (PEP)
Stress Engineering

Soapbox Sponsors

Cyta Therapeutics
Portal Instruments
Suono Bio
Wyss IInstitute


  • 8:00 am

  • Breakfast & Registration

    Hosted by:


  • 8:45 am

  • Chair’s Opening Remarks

    Chair’s Opening Remarks

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 9:00 am

  • Opening Keynote Address on Nanotechnology

    Opening Keynote Address on Nanotechnology

    Robert Langer, PhD
    David H. Koch Institute Professor, MIT

  • 9:50 am

  • Keynote: Enabling Patient Centric Therapies through Innovation in Personalized Healthcare and Drug Delivery

    We are delighted to welcome our 2015 industry keynote, Gail Wasserman, PhD, SVP, Biopharmaceutical Development, MedImmune. Joining Ms Wasserman on the stage is PODD veteran, Dr Anand Subramony, VP, Drug Delivery & Device Development, MedImmune. Together, they will speak on the following:

    Drug delivery and connected health technologies will deliver patient centric therapeutics and will transform how patients manage their health in the near future. As personalized health care strategies and companion diagnostics become reality, pharmaceutical and biotech companies are shifting to a “patient outcome”, or ‘pay for value’ based model. Pharma models are therefore evolving toward creating total solutions for patients rather than simply acting as a provider of dosage forms. Drug delivery plays an important role in this new paradigm. The emergence of biologics have led to the development of novel devices for parenteral delivery and has redefined the need for novel drug delivery technologies for biologics.

    Gail Wasserman, PhD
    SVP, Biopharmaceutical Development, MedImmune


    Anand Subramony, PhD
    VP, Drug Delivery & Device Development, MedImmune

  • 10:30 am

  • Networking Break & Partnering Meetings

  • 11:15 am

  • Licensing Drug Delivery Technologies for Oncology Therapeutics

    In this panel, we will hear from business development and licensing executives regarding current level of interest in drug delivery technologies for pipeline and launched drugs.

    • Licensing improved formulations of off-patent cancer drugs vs. enabling platform technologies for NCEs
    • Criteria used to evaluate novel oncology drug delivery systems
    • What stage and type of data is most attractive to pharmaceutical partners?
    • Types of formulations and technology platforms actively sought:
      • Nanotechnology-based/Nanomedicine
      • Antibody drug conjugates
      • Sustained release depots/implants
    • The value of partnering models
    • Structuring partnerships – platform vs. product licenses, option-based agreements, regional deals

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

    PJ Anand
    Founder, President & CEO, Alcyone Lifesciences Inc.

    Vahe Bedian, PhD
    Director, Oncology External Projects, AstraZeneca

    Yalia Jayalakshmi (Jaya), PhD
    Senior Director, Drug Delivery Technologies, Onyx Pharmaceutical

    Philippe Lopes-Fernandes
    SVP, Head of Global Licensing & Business Development, Merck Serono / EMD Serono

    Denis Patrick, PhD
    Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer

  • 12:00 pm

  • The SoloStar Injection Device: Foundation for a Versatile Platform

    Paul Jansen
    VP, Medical Device Development, Sanofi

    Rob Veasey
    Senior Sector Manager, Medical and Scientific, DCA Design International

    Bill Welch
    Chief Technology Officer, Phillips-Medisize Corporation

  • 12:40 pm

  • A Year in Review in Drug Delivery: A PharmaCircle Perspective

    Tugrul Kararli, PhD, MBA
    President and Founder, PharmaCircle

  • 12:55 pm

  • Luncheon & Partnering Meetings

  • 2:00 pm

  • Drug Delivery Presentations in Three Tracks


    Track One – Non-Injectable Formulation and Device Technologies
    Chaired by:
    Fernando Sallés, PhD
    VP, Head of Global Search, Teva Pharmaceuticals

    Presenting Companies:
    Damon Smith, PhD, CEO

    DisperSol Technologies, LLC
    Raj Sheel, MBA, VP, Business Development & Marketing

    IntraTab Labs, Inc.
    John McCarty, President

    Gemma Budd, Healthcare Business Manager

    Andrew Bellinger, MD, PhD, Chief Scientific Officer

    James Gibbons, Commercial Managerr

    Monosol RX
    Nozer Mehta, Vice President, Biologics

    Adam Feiler, CTO

    David Hava, PhD, CSO

    Colin Scott, Technology Director

    Tergus Pharmaceutical
    Vijendra Nalamothu, PhD, CEO and Founder

    Keren Leshem, MBA, CEO

    Vectura Limited
    Peter Hirst, Director, Corporate Development


    Track Two – Injectable Technologies
    Chaired by:
    Matthew Burke, PhD
    Head of Drug Delivery, Global Formulations, RD Platform Technology & Science, GSK

    Presenting Companies:
    Tod Lauerman, PhD, MBA, Corporate Development

    Reinhard Gabathuler, Chief Scientist

    Bio-Pact, LLC
    Kent Phelps, Co-Founder and CEO

    Caisson Biotech
    Breca Tracey, PhD, VP and Managing Director

    Christophe Barbe, CEO

    Cristal Therapeutics
    Joost Holthuis, PhD, CEO

    Cora Griffin, PhD, Business Development Manager

    Michael Hooven,  President and CEO

    Bob Getts, PhD, Chief Science Officer

    Innocore Pharmaceuticals
    Rob Steendam, MSc, PhD, Chief Technology Officer

    Novozymes Biopharma
    Svend Erik Licht, Global Head of Sales & Business Development
    Dan Shelly, PhD, MBA, Director, Business Development

    Serina Therapeutics
    Patricia Sinatra, SVP Business Development

    Tony Eglezos, PhD, MBA, VP, Business Development

    Gerhard Mayer, PhD, VP Business Development


    Track Three – Device Technologies
    Chaired by:
    Tomas Landh, MSc, PhD
    VP, Innovation Sourcing, Novo Nordisk

    Presenting Companies:
    Mark Tomai, Head of TLR and MTS Business Development

    Balda Healthcare
    Paul Wismer, MBA, International Business Development Manager

    Eric Dessertenne, PharmD, MBA, Head of Business Development and Commercial Operations

    Bio-Pact, LLC
    Kent Phelps, Co-Founder and CEO

    John Merhinge, Chief Commercial Officer

    Delta ModTech
    Dane Van Hulzen, Business Development

    Glide Pharmaceutical Technologies
    Mark Carnegie-Brown, PhD, CEO

    Michael Graffeo, Vice President, Business Development, Drug Delivery

    Mercator Medsystems
    Kirk Seward, PhD, Co-Founder, President, Chief Science and Technology Officer

    Isabelle Delcroix, Business Development Director

    Oval Medical Technologies
    Bastiaan deLeeuw, Head of Business Development

    PKA SoftTouch
    Dick Crawford, CEO

    Michael Weickert, PhD, Chief Executive Officer

    Terumo Medical Corporation
    Kevin Constable, Senior Director, Technology Development

    Michael Ratigan, SVP, Chief Commercial Officer


    There will be a 15-minute break at 4:00 pm.

    If you are interested in presenting in one of the tracks, please contact Meredith Sands at

  • 6:00 pm

  • Cocktail Reception


  • 8:00 am

  • Breakfast & Partnering Meetings

    Hosted by:


  • 8:30 am

  • Chair’s Welcome

    Chair’s Welcome

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 8:45 am

  • How We Built Moderna

    Stéphane Bancel joined Moderna in 2011 when it had one employee and patent and has assembled a company pioneering in the development of messenger RNA (mRNA) Therapeutics. It was recently named the #1 Disruptor on the third-annual CNBC Disruptor 50 list. For the second year in a row, CNBC recognizes Moderna as one of the country’s most ambitious and innovative companies changing the economy and overall business landscape.

    Stéphane Bancel
    CEO, Moderna Therapeutics

  • 9:30 am

  • Utilizing Nanotechnology to Advance Targeted Therapies and Personalized Medicine

    Omid Farokhzad, MD
    Associate Professor, Harvard Medical School

    Werner Cautreels, PhD
    President and CEO, Selecta Biosciences

    Michael Cima, PhD
    David H. Koch Professor of Engineering, MIT

    Drew Fromkin
    President and CEO, Blend Therapeutics

    Tom Lowery, PhD
    Chief Scientific Officer, T2 Biosystems

  • 10:15 am

  • Networking Break & Partnering Meetings

  • 11:00 am

  • Technology Spotlight: 3M’s Hollow Microstructured Transdermal System: A Novel High Volume Device for Reproducible Intradermal Delivery

    Mark Tomai, PhD
    Head of TLR and MTS Business Development
    3M Drug Delivery Systems Division

  • 11:20 am

  • Large Volume Drug Delivery – Are Patch Pumps the Answer?

    Due to the increasing need for improved parenteral delivery of high dose pharmaceuticals, especially biologics, a number of new wearable devices have been developed, such as patch pumps and bolus injectors. These devices enable self-administration and eliminate the need for multiple injections or infusions. This panel will discuss the current generation of wearable injection devices and the opportunities and challenges that lie ahead.

    • Key drawbacks of current devices – what should next generation devices address?
    • Beyond insulin, will patch pumps be cost-effective for other drugs such as mAbs?
    • How does the size of the device affect patient acceptability?
    • Implementing acceptance of wearable technology
    • Selecting the appropriate device, and device manufacturer-partner

    Christopher Coletta, PhD
    Independent Consultant / Former Director of Drug Delivery Innovation, Amgen

    Shawn Davis, PhD
    Principal Engineer, Device Strategy and Advanced Technology, Amgen

    Michael Graffeo
    VP, Business Development, Drug Delivery, Insulet Corporation

    David Haase
    Senior Manager, Device Development, Genentech

    Michael Hooven
    President and CEO, Enable Injections

    Iain Simpson
    Associate Director, Drug Delivery, Cambridge Consultants

  • 12:00 pm

  • Fifth Annual Company Spotlights

    In this session, we highlight four companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

    Shawn Davis, PhD
    Principal Engineer, Device Strategy and Advanced Technology

    Sanofi-Genzyme BioVentures
    Ann DeWitt, PhD
    Senior Director of Investments

    Abla Creasey, PhD
    Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences

    Eli Lilly and Company
    Divakar Ramakrishnan, PhD
    VP, Drug Delivery/Device R&D and Strategy

    Marie Schiller
    VP, Drug Delivery/Device R&D Innovation

  • 1:00 pm

  • Luncheon, Roundtables and Partnering Meetings

    The PODD Luncheon Roundtables are open to all delegates and feature a dedicated moderator with expertise in a particular area. The PODD Roundtables are an excellent way to engage in in-depth discussions and meet colleagues with similar interests. Grab your lunch and choose to join an optional round table or attend partnering meetings.

    Sponsored by:

    Biogen Logo

    Brain Delivery of Large Molecules
    Kapil Gupta, PhD
    Principal Scientist and Group Leader, Protein Pharmaceutical and Device Development, Biogen

    Atul Patel
    Director, Device Development, Biogen

    Delivery Strategies for Orphan CNS Diseases
    PJ Anand
    Founder, President and CEO, Alcyone Lifesciences

    Special Considerations in Topical Formulation for Proteins and Peptides
    Vijendra Nalamothu, PhD
    Co-Founder and CEO, Tergus Pharma

    How to Mitigate Recrystallization: Is Nanotechnology Ready to Offer Real Solutions?
    Andreas Bhagwani
    CEO, Nanologica

  • 2:00 pm

  • DDS Technology Soapbox@PODD sponsored by Pfizer

    This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    Presenting Companies:
    Cyta Therapeutics, Portal Instruments, Glysantis, Ligandal, Suono Bio, Wyss Institute, Arsia Therapeutics

    If you are interested in presenting on the Soapbox, please contact Meredith Sands at

  • 2:45 pm

  • Can RNA-based Therapeutics Really Deliver?

    Despite the therapeutic promise of RNA therapeutics, efficient and safe drug delivery remains a significant challenge. These therapeutics tend to have unfavorable physicochemical properties including negative charges, large molecular weight and size, and instability. A number of carrier systems are being developed for RNA therapeutics, including polymers, lipids, and conjugates, but selection of the delivery system depends on the therapeutics properties, type of target cells and the desired delivery route. This panel will discuss:

    • Key hurdles related to delivery of RNA therapeutics: siRNA, mRNA, RNAi
    • Delivery strategies and examples of recent successes
    • Collaborative approaches/models that are working
    • Commercialization prospects given low success rate of RNA drugs to-date

    Jessica Ballinger
    Senior Director, Protein Pharmaceutical Development, Biogen Idec

    Bob Brown, PhD
    CSO, SVP Research, Dicerna Pharmaceuticals

    Abla Creasey, PhD
    Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences, Janssen

    Jörg Kaufmann, PhD
    Chief Scientific Officer, Silence Therapeutics

    Muthiah (Mano) Manoharan, PhD
    Senior VP, Drug Discovery, Alnylam Pharmaceuticals

    Dave Rozema
    VP, Chemistry, Arrowhead Research

  • 3:45 pm

  • Improving Drug Delivery to the Back of the Eye

    There is an increasing need to successfully treat posterior eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy. Drug delivery to the back of the eye is challenging not only because of the anatomy of the eye and associated static and dynamic barriers, but also due to the growth of biologic therapeutics, and the challenges of delivering and stabilizing these more complex, large molecules. This panel will discuss goals and challenges of delivery, types of delivery systems showing promise for more effective delivery, and the benefits of collaborating in this space.

    James Cunningham, PhD
    Director, Ocular Drug Delivery, Allergan

    Ann Daugherty, PhD
    Senior Manager, Drug Delivery, Genentech

    Justin Hanes, PhD
    Lewis J. Ort Professor, Director, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

    Viral Kansara, PhD
    Investigator and Lab Head – Ocular Pharmacology and Drug Delivery, Novartis

    Jaymin Shah, PhD
    Research Fellow, Pfizer

    Stephen Yoo, MD
    Chief Medical Officer, Regenxbio